Spectrophotometric determination of vanadium(V) with methoxypromazine maleate and its application to vanadium steels and minerals

The reagent in 8-fold excess forms a violet species with vanadium(V) instantaneously in 1–3 M phosphoric acid. The absorption maximum is at 565 nm; the molar absorptivity is 1.65 × 104 l mol−1 cm−1. Beer's law is obeyed over the range 0.1–6.5 mg l−1 vanadium (V); the optimum range is 0.3–6.0 mg l−1; the Sandell sensitivity is 3.1 ng cm−2. The method is simple and selective. The method is applicable for the determination of vanadium in vanadium steels and minerals

Spectrophotometric method for the determination of thallium(III) with chlorpromazine hydrochloride

A simple, sensitive and rapid spectrophotometric method for the determination of thallium(III) is described, based on the reaction between chlorpromazine hydrochloride and thallium(III) in 4-7 M orthophosphoric acid at room temperature to form a pink species with an absorption maximum at 526 nm. Beer's law is obeyed over the concentration range 0.1-11.5 μg ml-1 of thallium(III), the optimum range being 1.0-10.0 μg ml-1. The Sandell sensitivity of the reaction is 0.0096 μg cm-2 and the molar absorptivity is 2.1 à 104 l mol-1 cm -1. The tolerance limit of the method towards various cations and anions usually associated with thallium has been determined. The method can be used for the determination of thallium in its alloys

Not Available

Not AvailableNot AvailableNot Availabl

A Review of the Effectiveness of Neuroimaging Modalities for the Detection of Traumatic Brain Injury

The incidence of traumatic brain injury (TBI) in the United States was 3.5 million cases in 2009, according to the Centers for Disease Control and Prevention. It is a contributing factor in 30.5% of injury-related deaths among civilians. Additionally, since 2000, more than 260,000 service members were diagnosed with TBI, with the vast majority classified as mild or concussive (76%). The objective assessment of TBI via imaging is a critical research gap, both in the military and civilian communities. In 2011, the Department of Defense (DoD) prepared a congressional report summarizing the effectiveness of seven neuroimaging modalities (computed tomography [CT], magnetic resonance imaging [MRI], transcranial Doppler [TCD], positron emission tomography, single photon emission computed tomography, electrophysiologic techniques [magnetoencephalography and electroencephalography], and functional near-infrared spectroscopy) to assess the spectrum of TBI from concussion to coma. For this report, neuroimaging experts identified the most relevant peer-reviewed publications and assessed the quality of the literature for each of these imaging technique in the clinical and research settings. Although CT, MRI, and TCD were determined to be the most useful modalities in the clinical setting, no single imaging modality proved sufficient for all patients due to the heterogeneity of TBI. All imaging modalities reviewed demonstrated the potential to emerge as part of future clinical care. This paper describes and updates the results of the DoD report and also expands on the use of angiography in patients with TBI

Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation

Acute myeloid leukemia (AML) patients often undergo allogeneic hematopoietic cell transplantation (alloHCT) in first complete remission (CR). We examined the effect of depth of clinical response, including incomplete count recovery (CRi) and/or measurable residual disease (MRD), in patients from the Center for International Blood and Marrow Transplantation Research (CIBMTR) registry. We identified 2492 adult patients (1799 CR and 693 CRi) who underwent alloHCT between January 1, 2007 and December 31, 2015. The primary outcome was overall survival (OS). Multivariable analysis was performed to adjust for patient-, disease-, and transplant-related factors. Baseline characteristics were similar. Patients in CRi compared to those in CR had an increased likelihood of death (HR: 1.27; 95% confidence interval: 1.13-1.43). Compared to CR, CRi was significantly associated with increased non-relapse mortality (NRM), shorter disease-free survival (DFS), and a trend toward increased relapse. Detectable MRD was associated with shorter OS, shorter DFS, higher NRM, and increased relapse compared to absence of MRD. The deleterious effects of CRi and MRD were independent. In this large CIBMTR cohort, survival outcomes differ among AML patients based on depth of CR and presence of MRD at the time of alloHCT. Further studies should focus on optimizing post-alloHCT outcomes for patients with responses less than CR